Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission

Mark B Geyer^{1

2}, Martin S Tallman¹

Affiliations

¹ a Department of Medicine , Leukemia Service, Memorial Sloan Kettering Cancer Center , New York , NY , USA.
² b Center for Cell Engineering , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

Comment

Mark B Geyer et al. Leuk Lymphoma. 2018 Feb.

. 2018 Feb;59(2):269-271.

doi: 10.1080/10428194.2017.1355971. Epub 2017 Jul 28.

Mark B Geyer^{1

2}, Martin S Tallman¹

¹ a Department of Medicine , Leukemia Service, Memorial Sloan Kettering Cancer Center , New York , NY , USA.
² b Center for Cell Engineering , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

No abstract available

Comment on

Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
Saygin C, Papadantonakis N, Cassaday RD, Liedtke M, Fischer K, Dunn T, Patel BJ, Sobecks R, Kalaycio M, Sekeres MA, Mukherjee S, Gerds AT, Hamilton BK, Carraway HE, Advani AS. Saygin C, et al. Leuk Lymphoma. 2018 Feb;59(2):363-371. doi: 10.1080/10428194.2017.1344842. Epub 2017 Jul 11. Leuk Lymphoma. 2018. PMID: 28693363